/

Investors / United States / Aditum Bio

Aditum Bio

Venture capital · Oakland, CA, United States · North America

aditumbio.com

Aditum Bio is a biotech venture capital firm that forms and operates companies around acquired drug candidates. It focuses on the translation phase of drug development, advancing clinic-ready therapies into Phase 2 clinical trials through an in-house operating model.

Invests inHealthcare & Biotech

In its own wordsbiotechdrug developmenttherapeuticsclinical trialslife sciences

Your fit with Aditum Bio

Three questions about your startup

See how your round matches what it backs, point by point.

Or find every investor that fits
3portfolio companies
1funding rounds on recordnamed lead in 0 of 1 that name one
1rounds, last 12 months

Aditum Bio lists 4 companies on its own site, 3 of them checked. It is named in 1 funding round. Its largest theme is Healthcare & Biotech (100%).

Counts come from funding rounds that name Aditum Bio, complete from mid-2025: earlier rounds appear only when they were reported later. Reports often leave out co-leads, so a firm may have led more rounds than shown. Round amounts and full round histories are on Fundup AI.

Entry stage

share of companies by the stage it came in at · n=0

Counted only where the round is where it came in: a pre-seed or seed round, or a later round after the company raised without it. Aditum Bio does not state its stages on its site.

No round on record shows where Aditum Bio came in. Rounds are complete from mid-2025, so a later round may be a follow-on into a company it backed earlier; those are left out.

Activity by year

rounds it joined, last 10 years
Show as a table
Funding rounds per year
TotalRounds it led
'1700
'1800
'1900
'2000
'2100
'2200
'2300
'2400
'2500
'2610

Investment themes

share of its 3 companies with a theme; a company can have two

This firmAll checked companies

Show as a table
Investment themes
This firmAll checked companies
Healthcare & Biotech100%17%

Shares portfolio companies with

firms that back the same companies, not always in the same round
Show as a table
Co-investors
Share
GV1

All co-investors

Its portfolio companies

where they are based, and what their own sites show

Headquarters

Site status

  • Site answers3100%
  • No longer answers00%
  • Points to another company00%
  • Parked or sold domain00%

A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.

Compare Aditum Bio head to head

portfolio size, rounds, entry stages, themes and the companies both back

Three or more firms at once: portfolio overlap.

Team

22 people, as Aditum Bio's own site lists them
  • Joe JimenezCo-Founder and Managing Director
  • Dr. Mark FishmanCo-Founder and Chair of the Scientific Advisory Board
  • Praveena KandulaPrincipal
  • Chris KleeOperating Partner
  • Yousef BadranEntrepreneur-in-Residence
  • Matthew Ambros
  • Susie PhillipsExecutive Assistant
  • Monica FinnController
  • Hayden GrandeSr. Executive Assistant
  • Mat LaFountainProcurement Manager
  • Emily HealeyOperations Manager
  • Tony DiBonaChief Financial Officer
Show all 22
  • Brian Ridgeway
  • Shyanne AliSVP Quality
  • Chris Daige
  • Ricardo Dolmetsch
  • Matt Fitzpatrick
  • Dr. Don GanemScientific Advisor
  • sophie Hanscom
  • Chamara Jayesinghe
  • Denise Jones-Abud
  • Scott PlevyHead of Immunology

Names and roles from this page of its site; VCinfo keeps nothing else about them. Listed here and want to be removed? Write to us.

Recent portfolio activity

when companies last raised with Aditum Bio
DateCompanyStage
25 Jun 2026Oblenio Bioobleniobio.comSeries B

Round details for Aditum Bio

Amounts, full round histories and every co-investor in Aditum Bio's rounds are on Fundup AI. VCinfo covers investors and their portfolios.

See rounds on Fundup AI →

Portfolio

3 companies checked against their own sites
CompanyWhat it doesThemesFirst round with itEvidence
Kalexo Biokalexobio.comKalexo Bio is advancing dual-targeting siRNA therapeutics to address the most critical unmet needs in cardiovascular disease.
Healthcare & Biotech
Portfolio page
Oblenio Bioobleniobio.com · United StatesOblenio Bio aims to transform the treatment of refractory autoimmune diseases
Healthcare & Biotech
Jun 2026Series BFunding round
Trames Biotramesbio.comTrames Bio is developing a new class of therapies designed to precisely and reversibly control neuronal activity to treat chronic pain
Healthcare & Biotech
Portfolio page

About this data

site last read 5 Nov 2026
The homepage of Aditum Bio, as last read
aditumbio.com as VCinfo last read it
Site
aditumbio.com
Last read
5 Nov 2026
Watching since
5 Nov 2026
Rounds since
25 Jun 2026
Companies checked
3

Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.

How we grade the data

Free account · no card

Get Aditum Bio's profile as data

Pull Aditum Bio's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.

Work email, sign-in link by email. Already have an account? Log in
  • Ask AI5 plain-English investor searches a day
  • Full listsEvery portfolio row and two-firm overlap
  • API and MCP100 REST or MCP calls a month, one key
  • AlertsFollow 5 investors for portfolio and fund changes
VCinfo API
$ curl -H "X-API-Key: YOUR_KEY" \
  https://api.vcinfo.io/v1/firms/aditumbio.com

# also
GET /v1/firms/aditumbio.com/portfolio
GET /v1/firms/aditumbio.com/coinvestors
GET /v1/firms/aditumbio.com/news
The same data as an MCP server for Claude, Cursor and other AI tools. Set up MCP · Docs · Pricing